Dr. Marty Makary: FDA Commissioner on Vaccines, Chronic Diseases & Drug Prices | TUH #229

Makary dedicates a long segment to the history of HRT. He explains that the 2002 WHI study was designed to prove harm, and its leaders framed a non-significant finding as a definitive cancer verdict. This led to the FDA’s black box warning and decades of fear. He shares that dissenting scientists were silenced — one lost NIH funding. The result was 50 million women denied a therapy that not only improves quality of life but also cuts the risk of the leading cause of death in women. Makary emphasizes that many physicians now consider 10 years post-menopause the window of maximum benefit; after that, the risk–benefit ratio may shift. The protocol is to start early and use the safest available formulation (often bioidentical estradiol with micronized progesterone).

Makary uses the dye ban to illustrate how the FDA is now listening to real-world evidence — parents’ observations. He says the old medical establishment would demand a multi-year randomized controlled trial while ignoring the fact that no child is dependent on these dyes. By acting after 35 years of deliberation, he signals that precautionary principle wins when harm is plausible and avoidable. He ties this to the over-medicalization of childhood behavior: kids are drugged for disorders that may be rooted in diet and environment.

Makary dedicates several minutes to the microbiome as the biggest unaddressed frontier in medicine. He details the Mayo Clinic study outcomes and invokes Dr. Fleming’s 1928 warning about antibiotic overuse causing resistance and ‘evil.’ He argues that the explosion in childhood chronic diseases — asthma, ADHD, obesity, autoimmune conditions — cannot be understood without considering early-life microbiome disruption. He links this to the earlier themes: ultra-processed foods further perturb the microbiome, and the medical system ignores root causes. The protocol is a plea for restraint and a shift toward preventive gut health.

Makary paints a vivid picture: kids are wrenched from deep sleep in the dark, put on a bus, and then sit under micro-flashing fluorescent lights for seven hours with little outdoor time. Combined with high-sugar meals, this drives insulin spikes and behavioral issues. Instead of fixing the environment, we label the child as having oppositional defiant disorder and drug them. He uses this to illustrate the medicalization of ordinary life and the need to address root causes like light, diet, and movement.

Makary describes the change as part of a broader ‘radical transparency’ push. The idea had been floated for 20 years but never implemented. By making these letters public, he argues the FDA is empowering patients, curbing corporate spin, and restoring trust. He connects this to the agency’s shift from a paternalistic gatekeeper to an honest broker of data. This also dovetails with his decision to release internal documents on myocarditis and COVID shots in children, underscoring a new culture of disclosure.

Makary delves into the internal dissent: a shouting match erupted when lead investigators presented the conclusion as a fait accompli. One dissenter lost his NIH funding for disagreeing. He argues this was a personality-ego battle camouflaged as high science, and the media’s framing caused doctors to stop prescribing HRT. The black box warning stuck for 22 years. By removing it, Makary says the FDA is correcting a profound injustice. He acknowledges that modern bioidentical hormones and different progestins further reduce any theoretical risk. The decision also signals that the agency will no longer tolerate groupthink that harms patients.

Makary contrasts the prior administration’s priority (fighting misinformation) with his own (delivering cures and healthier food for kids). The dye ban is just one part of a broader food safety overhaul: he plans to address over 1,000 chemicals permitted in the US food supply that are banned in Europe, reform the GRAS (Generally Recognized As Safe) loophole, and send enforcement warning letters to companies making misleading claims. He says the change came from listening to parents who witnessed their children’s behavior improve when dyes were removed and deteriorate when reintroduced — a form of real-world evidence he now respects.

Makary argues that the old pyramid was ‘written by the industry’ to sell products, not to promote health. The new guidelines will explicitly talk about the quality of whole foods — fruits, vegetables, properly raised animal products — and the importance of protein for muscle preservation and metabolic health. He also stresses that the gut microbiome is profoundly influenced by food quality, linking the new guidelines to the emerging science on insulin resistance, inflammation, and chronic disease. The change is expected to ripple through school lunch programs, WIC, and doctor counseling.

Makary frames this as a return to the FDA’s core job: evaluating whether data supports claims, not succumbing to corporate or political influence. He explicitly says ‘we're not going to blindly rubber stamp mRNA COVID vaccines every year in perpetuity with no data.’ The recent failure of an mRNA flu vaccine in seniors is proof that the new approach is real — the product won’t be approved. He also promises full transparency on adverse events, citing the release of internal documents on myocarditis and COVID shots in children. While he stresses he is not removing any existing vaccines, he wants the public to have complete information to make informed decisions, and expects the CDC to re-evaluate its recommendation schedule.

Makary describes a case where 12 children received the therapy: three gained normal hearing and seven improved. His team contacted the company within days and granted the voucher. He says this is the first time the FDA has piloted such a rapid program. The goal is to break the paternalistic ‘we must protect you from unapproved therapies’ mindset, replacing it with a sense of urgency for cures. He notes that lowering R&D costs (via eliminating unnecessary animal testing and streamlining trials) will further encourage innovation and competition, ultimately lowering drug prices.